COVID-19 Vaccination Quick Links

Current as of June 6, 2022

Numerous tools and resources are available to inform the COVID-19 vaccination efforts of healthcare providers, including ASPR TRACIE’s technical assistance response focused on the healthcare facility response during the first six months of the vaccine roll out. ASPR TRACIE created this list to assist clinicians in quickly finding the most relevant and current information about COVID-19 vaccines available in the United States, their intended populations, recommendations for their use, effectiveness and safety issues, potential adverse events to be aware of, the effects of SARS-CoV-2 variants on the vaccinated, and resources to help communicate with patients. Additional resources are also listed to access more detailed information.

Vaccines Available in the U.S.

**Pfizer-BioNTech**

- **FDA approved (COMIRNATY)**
  - 2 dose primary series in individuals 16 years of age & older (undiluted gray cap or diluted purple cap)

- **FDA Emergency Use Authorization (EUA)**
  - 2 dose primary series in individuals 12 years of age & older (undiluted gray cap or diluted purple cap) or ages 5-11 (diluted orange cap)
  - 3rd dose in primary series for certain immunocompromised individuals 12 years of age & older (undiluted gray cap or diluted purple cap) or ages 5-11 (diluted orange cap)
  - Booster dose at least 5 months after primary series with an approved or authorized Pfizer-BioNTech vaccine for those ages 5 & older (at least 3 months after primary series for those who are moderately or severely immunocompromised)

- Booster dose at least 5 months after the primary series for those ages 18 & older (at least 3 months after primary series for those who are moderately or severely immunocompromised)

- 2nd booster at least 4 months after the 1st booster for those 50 years of age & older and certain immunocompromised individuals 12 years of age & older

**Moderna**

- **FDA approved (Spikevax)**
  - 2 dose primary series in individuals 18 years of age & older
  - 3rd dose in primary series for certain immunocompromised individuals 18 years of age & older
  - Booster dose at least 5 months after primary series for those ages 18 & older (at least 3 months after primary series for those who are moderately or severely immunocompromised)

- 2nd booster dose at least 4 months after 1st booster for those 50 years of age & older and certain immunocompromised individuals 18 years of age & older

**Johnson & Johnson/Janssen**

- **FDA EUA**
  - 1 dose in individuals 18 years of age & older
  - 2nd dose in primary series for certain immunocompromised individuals 18 years of age & older
  - Booster dose at least 2 months after primary dose for those ages 18 and older, including those who are moderately or severely immunocompromised

The **recommended timing** of the 2nd dose for those who received an mRNA vaccine for their primary series is dependent upon age, sex, risk of severe disease, rates of community transmission, and immunocompromised status.

FDA authorized heterologous, or mix-and-match, booster doses using any authorized vaccine. The timing of the booster dose and eligible population are based on the vaccine used for the primary series.

*CDC preferentially recommends* use of mRNA vaccines due to the rare but noted risk of thrombosis with thrombocytopenia syndrome associated with the Johnson & Johnson/Janssen vaccine. The FDA **limits** authorized use of the Johnson & Johnson/Janssen vaccine to those 18 years of age and older for whom other authorized/approved vaccines are not clinically appropriate or accessible or would not otherwise receive a COVID-19 vaccine.
### Recommendations

Advisory Committee on Immunization Practices COVID-19 Vaccine Recommendations  
CDC Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the U.S.

#### SARS-CoV-2 Variants

- **Variants of the Virus**

#### Effectiveness

- **COVID-19 Vaccine Effectiveness**

#### Safety

- **Ensuring COVID-19 Vaccine Safety in the U.S.**

#### Potential Adverse Events

- **Common Side Effects**
  - Anaphylaxis
  - Guillain-Barre Syndrome
  - Myocarditis/Pericarditis
  - Thrombosis with Thrombocytopenia

### Communicating with Patients

- **Be a COVID-19 Vaccine Champion Webinar**
- **Building Confidence in COVID-19 Vaccines**
- **Communication Resources for COVID-19 Vaccines**
- **Vaccines**
- **COVID-19 Vaccine Education**
- **COVID-19 Vaccine for Children**
- **Immunization Communications Resource Portal**
- **Vaccine Communications Tips**
- **Vaccine Recipient Education**

### Additional Resources

- **ASPR TRACIE:** [COVID-19 Vaccine Resources Collection](#)
- **CDC:** [Vaccines for COVID-19](#)
- **FDA:** [COVID-19 Vaccines](#)
- **NIH:** [COVID-19 Vaccines](#)